
Opinion|Videos|January 8, 2024
Study Conclusions and Its Implications
Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.
Advertisement
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
2
Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist
3
Selecting Patients With High-Risk Prostate Cancer for Perioperative ARPI Therapy
4
64Cu-SAR-bisPSMA Earns FDA Breakthrough Designation in Recurrent Prostate Cancer
5

